Lupin Expands GLP-1 Portfolio with Galenicum Semaglutide Deal
Mumbai: Global pharmaceutical major Lupin Limited on Tuesday announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA (LAHSA) with Spain-based Galenicum Health, S.L.U. for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist.
Under the agreement, Galenicum will be responsible for the development, manufacturing and supply of the product, while Lupin will lead regulatory submissions, approvals, commercialisation and distribution across 23 countries, including Canada, Europe, Southeast Asia and Latin America. The partnership is expected to strengthen Lupin’s presence in the rapidly expanding global diabetes and obesity treatment markets.
“Our partnership with Galenicum marks a strategic milestone in strengthening Lupin’s Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major public health priority, Semaglutide stands out as a critical therapy,” said Fabrice Egros, President, Corporate Development, Lupin. He added that Lupin’s established commercial footprint across key global markets positions the company to scale access to GLP-1 therapies and reinforce its commitment to affordable, high-quality medicines.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, helps regulate blood sugar levels and appetite. It is primarily prescribed for adults with Type 2 diabetes, alongside diet and exercise, and is also used for long-term weight management in adults with obesity or overweight conditions.
Commenting on the collaboration, Joaquim Domingo, Co-founder of Galenicum, said the partnership aligns with the company’s strategy to scale high-impact volumes of Semaglutide globally. He noted that Galenicum has made significant investments in its GLP-1 development pipeline to address the growing global demand for these therapies, with the aim of becoming a leading B2B player in the GLP-1 segment.
The agreement adds to Lupin’s recent efforts to expand its global GLP-1 portfolio and follows a series of strategic licensing partnerships aimed at strengthening its position in complex and high-growth therapeutic segments.
